SG11202000996UA - Antibody-drug conjugate preparation and lyophilization for same - Google Patents
Antibody-drug conjugate preparation and lyophilization for sameInfo
- Publication number
- SG11202000996UA SG11202000996UA SG11202000996UA SG11202000996UA SG11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA
- Authority
- SG
- Singapore
- Prior art keywords
- lyophilization
- antibody
- same
- drug conjugate
- conjugate preparation
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 238000004108 freeze drying Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017160071 | 2017-08-23 | ||
PCT/JP2018/030882 WO2019039483A1 (fr) | 2017-08-23 | 2018-08-22 | Préparation de conjugué anticorps-médicament et lyophilisation associée |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000996UA true SG11202000996UA (en) | 2020-03-30 |
Family
ID=65438975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000996UA SG11202000996UA (en) | 2017-08-23 | 2018-08-22 | Antibody-drug conjugate preparation and lyophilization for same |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210128741A1 (fr) |
EP (1) | EP3673918A4 (fr) |
JP (2) | JP7204651B2 (fr) |
KR (1) | KR20200044044A (fr) |
CN (1) | CN110944667A (fr) |
AU (1) | AU2018320470A1 (fr) |
BR (1) | BR112020003474A2 (fr) |
CA (1) | CA3073383C (fr) |
IL (1) | IL272721A (fr) |
MA (1) | MA49987A (fr) |
SG (1) | SG11202000996UA (fr) |
TW (1) | TW201919710A (fr) |
WO (1) | WO2019039483A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018210081A1 (en) * | 2017-01-17 | 2019-08-08 | Daiichi Sankyo Company, Limited | Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate |
US20220080376A1 (en) * | 2019-02-15 | 2022-03-17 | The Regents Of The University Of California | Methods for converting colloidal systems to resuspendable/redispersable powders that preserve the original properties of the colloids |
MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
WO2020192693A1 (fr) * | 2019-03-26 | 2020-10-01 | 荣昌生物制药(烟台)股份有限公司 | Préparation pharmaceutique de conjugué médicament-anticorps anti-her2 |
BR112021023901A2 (pt) * | 2019-05-29 | 2022-01-18 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer |
WO2021027851A1 (fr) * | 2019-08-12 | 2021-02-18 | 凯惠科技发展(上海)有限公司 | Anticorps trop2, son procédé de préparation, conjugué et utilisation associée |
AU2021243073A1 (en) * | 2020-03-25 | 2022-10-13 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody drug conjugate and use thereof |
WO2021223048A1 (fr) * | 2020-05-03 | 2021-11-11 | 上海美雅珂生物技术有限责任公司 | Conjugué anticorps-médicament et sa préparation |
CN112361726B (zh) * | 2020-10-27 | 2022-09-02 | 北京诺康达医药科技股份有限公司 | 一种冻干制剂水分控制方法及其应用 |
US20240058463A1 (en) * | 2020-12-18 | 2024-02-22 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
CA3235106A1 (fr) * | 2021-10-19 | 2023-04-27 | Sixiang FAN | Preparation pharmaceutique de conjugue, methode de preparation et utilisation connexe |
WO2024041587A1 (fr) * | 2022-08-25 | 2024-02-29 | 启德医药科技(苏州)有限公司 | Composition pharmaceutique de conjugué anticorps-médicament |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
BR122014028365B8 (pt) | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
CA2785941C (fr) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Cellules produisant des compositions d'anticorps |
BRPI0213846B8 (pt) | 2001-11-01 | 2021-05-25 | Uab Research Foundation | composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos |
EP1539239A4 (fr) | 2002-07-02 | 2005-09-14 | Smithkline Beecham Corp | Nouvelle formulation stable |
CN102940889A (zh) * | 2003-05-14 | 2013-02-27 | 伊缪诺金公司 | 药物缀合物组合物 |
CA2615122A1 (fr) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Formulations d'immunoconjugue |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
EP2376110B1 (fr) | 2009-01-09 | 2019-03-13 | Seattle Genetics, Inc. | Régimes posologiques hebdomadaires pour des conjugués anticorps anti-cd30 vc-pab-mmae - médicament |
TW201247222A (en) * | 2011-04-21 | 2012-12-01 | Daiichi Sankyo Co Ltd | Antibody liquid formulation |
EP3632471A1 (fr) | 2012-10-11 | 2020-04-08 | Daiichi Sankyo Company, Limited | Conjugués anticorps-médicament |
EP2910573B1 (fr) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile |
EP4035689A1 (fr) | 2012-12-13 | 2022-08-03 | Immunomedics Inc. | Dosages d'immuno-conjugués d'anticorps et de sn-38 pour améliorer l'efficacité et réduire la toxicité |
AU2014228172B2 (en) | 2013-03-15 | 2018-12-06 | Abbvie Deutschland Gmbh & Co.Kg | Anti-EGFR antibody drug conjugate formulations |
PT3060256T (pt) | 2013-10-25 | 2019-07-19 | Bayer Pharma AG | Uma nova formulação estável |
KR102535900B1 (ko) | 2013-12-25 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
SG10201800210TA (en) | 2014-01-31 | 2018-02-27 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
EA201692002A1 (ru) | 2014-04-07 | 2017-01-30 | Сиэтл Дженетикс, Инк. | Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство |
KR102127623B1 (ko) * | 2014-04-10 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
ES2754348T3 (es) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
EP4180455A1 (fr) * | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Procédé de fabrication sélective d'un conjugué anticorps-médicament |
WO2017009255A1 (fr) * | 2015-07-10 | 2017-01-19 | Synthon Biopharmaceuticals B.V. | Compositions comprenant des conjugués anticorps-duocarmycine |
AU2017341000A1 (en) * | 2016-10-07 | 2019-04-11 | Daiichi Sankyo Company, Limited | Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate |
AU2017377233A1 (en) * | 2016-12-12 | 2019-06-13 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
AU2018210081A1 (en) | 2017-01-17 | 2019-08-08 | Daiichi Sankyo Company, Limited | Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate |
CN117838880A (zh) * | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
SG11202000997YA (en) * | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
WO2019230645A1 (fr) * | 2018-05-28 | 2019-12-05 | 第一三共株式会社 | Traitement du cancer à her2 muté par administration d'un conjugué anticorps anti-her2-médicament |
CN112566942A (zh) * | 2018-07-25 | 2021-03-26 | 第一三共株式会社 | 用于制造抗体-药物缀合物的有效方法 |
EA202190403A1 (ru) * | 2018-07-31 | 2021-05-24 | Дайити Санкио Компани, Лимитед | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство |
AU2019320336A1 (en) * | 2018-08-06 | 2021-03-04 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
-
2018
- 2018-08-22 BR BR112020003474-6A patent/BR112020003474A2/pt unknown
- 2018-08-22 EP EP18849166.6A patent/EP3673918A4/fr active Pending
- 2018-08-22 CN CN201880054464.7A patent/CN110944667A/zh active Pending
- 2018-08-22 CA CA3073383A patent/CA3073383C/fr active Active
- 2018-08-22 WO PCT/JP2018/030882 patent/WO2019039483A1/fr unknown
- 2018-08-22 KR KR1020207007993A patent/KR20200044044A/ko not_active Application Discontinuation
- 2018-08-22 SG SG11202000996UA patent/SG11202000996UA/en unknown
- 2018-08-22 US US16/640,914 patent/US20210128741A1/en active Pending
- 2018-08-22 AU AU2018320470A patent/AU2018320470A1/en active Pending
- 2018-08-22 JP JP2019537642A patent/JP7204651B2/ja active Active
- 2018-08-22 MA MA049987A patent/MA49987A/fr unknown
- 2018-08-22 TW TW107129228A patent/TW201919710A/zh unknown
-
2020
- 2020-02-17 IL IL272721A patent/IL272721A/en unknown
-
2022
- 2022-12-28 JP JP2022211501A patent/JP2023036900A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL272721A (en) | 2020-04-30 |
TW201919710A (zh) | 2019-06-01 |
WO2019039483A1 (fr) | 2019-02-28 |
BR112020003474A2 (pt) | 2020-10-20 |
MA49987A (fr) | 2020-07-01 |
EP3673918A4 (fr) | 2021-05-19 |
RU2020111448A (ru) | 2021-09-24 |
JPWO2019039483A1 (ja) | 2020-10-01 |
CN110944667A (zh) | 2020-03-31 |
KR20200044044A (ko) | 2020-04-28 |
EP3673918A1 (fr) | 2020-07-01 |
CA3073383A1 (fr) | 2019-02-28 |
CA3073383C (fr) | 2023-10-31 |
RU2020111448A3 (fr) | 2021-11-29 |
JP7204651B2 (ja) | 2023-01-16 |
US20210128741A1 (en) | 2021-05-06 |
AU2018320470A1 (en) | 2020-02-13 |
JP2023036900A (ja) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272721A (en) | Antibody-drug conjugate preparation and lyophilization method | |
IL268102A (en) | Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate | |
ZA202003833B (en) | Conjugates and preparation and use thereof | |
EP3626825A4 (fr) | Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament | |
IL290959A (en) | Preparations containing antibody-drug conjugates and methods for their production | |
IL291337A (en) | Camptothecin derivative and its conjugate | |
ZA202001219B (en) | Bcma monoclonal antibody-drug conjugate | |
EP3473270A4 (fr) | Conjugué anticorps-médicament | |
HK1231367A1 (zh) | 抗體藥物偶聯物、試劑和製備方法及其治療用途 | |
SG11202101719PA (en) | Antibody-drug conjugate and application thereof | |
IL253712A0 (en) | Mysterlein derivatives for coupling and healing | |
EP3380126A4 (fr) | Conjugués anticorps-médicament comprenant des lieurs ramifiés et procédés connexes | |
HK1243957B (zh) | 抗erbb2抗體-藥物偶聯物及其組合物、製備方法和應用 | |
EP3501548A4 (fr) | Conjugué anticorps-médicament ciblant le facteur tissulaire | |
EP3412315A4 (fr) | Conjugué anticorps anti-her2-médicament et son utilisation | |
EP3617218A4 (fr) | Conjugué dihydroartémisinine-stéroïde, son procédé de préparation et son utilisation | |
IL275208A (en) | Hsp90-targeting conjugates and formulations thereof | |
EP3599249A4 (fr) | Conjugué anticorps anti-5t4-médicament et son utilisation | |
IL265838A (en) | Conjugation of an antibody with a drug modified by cysteine and a method for its preparation | |
IL277791A (en) | Hsp90-targeting conjugates and formulations thereof | |
IL269321A (en) | drug-polymer couple | |
IL266112A (en) | Antibodies against edb and antibody-drug conjugates | |
FI3666787T3 (fi) | Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja | |
EP3441088A4 (fr) | Conjugué anticorps-médicament comprenant un anticorps modifié | |
EP3666788A4 (fr) | Dérivés d'hémiasterline et conjugués anticorps-médicament les comprenant |